ExpreS2ion Biotech (EXPRS2) BioStock Life Science summary

Company Overview and Technology Platform

• Focuses on developing the breast cancer vaccine ES2B-C001, leveraging the ExpreS2 protein expression platform and proprietary VLP technology, with over 15 years of clinical validation up to phase III in other vaccine projects.

• Holds a 34% stake in AdaptVac, co-founded to utilize VLP technology integral to ES2B-C001.

• ExpreS2ion's proprietary protein production platform supports both a vaccine pipeline and CRO business.

• Listed on Nasdaq First North Growth Market since 2016, with 100% ownership of ExpreS2ion Biotechnologies ApS.

Breast Cancer Market and Unmet Need

• HER2 is overexpressed in about 25% of breast cancer tumors, associated with aggressive disease and higher mortality.

• Over 180,000 annual diagnoses of HER2+ breast cancer in major markets, with significant subpopulations for HER2low and HER2neg.

• Breast cancer causes approximately 685,000 deaths globally each year.

ES2B-C001 Vaccine Design and Advantages

• Combines full-length HER2 antigen with highly immunogenic VLP technology for a strong polyclonal antibody response, presenting a wide range of epitopes.

• Targets all four HER2 epitopes, aiming to address resistance and side effects seen in current monoclonal antibody treatments.

• Off-the-shelf, scalable, cost-effective, and validated for safety.

• Inspired by successful VLP vaccines like Cervarix and Gardasil, with commercialization strategy considering premium pricing due to clinical advantages.

• Pricing is expected to be competitive with monoclonal antibodies, which can exceed $100,000 per treatment.